FORMYCON AG (FYB.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:FYB - DE000A1EWVY8 - Common Stock
FYB.DE Key Statistics, Chart & Performance
The current stock price of FYB.DE is 24.25 EUR. In the past month the price increased by 10.73%. In the past year, price decreased by -51.45%.
FYB.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| ARGX.BR | ARGENX SE | 72.78 | 48.17B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.41B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 837.02M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 699.13M | ||
| 6IV.DE | INVENTIVA SA | N/A | 651.37M |
Related stock screener links
About FYB.DE
Company Profile
Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 245 full-time employees. The company went IPO on 2010-12-20. The firm is engaged in providing biosimilar drugs and formulations. The firm focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.
Company Info
FORMYCON AG
Fraunhoferstrasse 15, Planegg
Martinsried BAYERN DE
Employees: 250
Phone: 4989864667100
FORMYCON AG / FYB.DE FAQ
What does FORMYCON AG do?
Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 245 full-time employees. The company went IPO on 2010-12-20. The firm is engaged in providing biosimilar drugs and formulations. The firm focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.
Can you provide the latest stock price for FORMYCON AG?
The current stock price of FYB.DE is 24.25 EUR. The price decreased by -1.42% in the last trading session.
Does FYB stock pay dividends?
FYB.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of FYB stock?
FYB.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does FORMYCON AG have?
FORMYCON AG (FYB.DE) currently has 250 employees.
Can you provide the ownership details for FYB stock?
You can find the ownership structure of FORMYCON AG (FYB.DE) on the Ownership tab.
FYB.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to FYB.DE. When comparing the yearly performance of all stocks, FYB.DE is a bad performer in the overall market: 93.43% of all stocks are doing better.
FYB.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FYB.DE. Both the profitability and financial health of FYB.DE have multiple concerns.
FYB.DE Financial Highlights
Over the last trailing twelve months FYB.DE reported a non-GAAP Earnings per Share(EPS) of -9.6. The EPS decreased by -339.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.86% | ||
| ROE | -41.58% | ||
| Debt/Equity | 0.02 |
FYB.DE Forecast & Estimates
14 analysts have analysed FYB.DE and the average price target is 52.63 EUR. This implies a price increase of 117.04% is expected in the next year compared to the current price of 24.25.
For the next year, analysts expect an EPS growth of -125.05% and a revenue growth -8.28% for FYB.DE